BioneerCorp

Chart & Performance

D1W1MN

P/E

—

P/S

1.82

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

4.59%

Rev. gr., 5y

61.34%

Revenues

263.24b

+20.53%

Net income

-10.59b

CFO

4.14b

-53.03%

Dividend

Mar 15, 20220.285 KRW/sh

Profile

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.

URL

https://www.bioneer.co.kr/

IPO date

Dec 29, 2005

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	263,236,803 20.53%	218,394,453 -2.39%	223,743,694 8.10%
Cost of revenue	226,744,852	176,032,647	154,757,438
Unusual Expense (Income)
NOPBT	36,491,951	42,361,807	68,986,256
NOPBT Margin	13.86%	19.40%	30.83%
Operating Taxes	6,851,604	(1,217,551)	14,079,211
Tax Rate	18.78%		20.41%
NOPAT	29,640,347	43,579,357	54,907,045
Net income	(10,587,030) -187.66%	12,076,879 -55.53%	27,159,524 -53.09%
Dividends
Dividend yield
Proceeds from repurchase of equity			146,249
BB yield			-0.01%
Debt
Debt current	30,282,504	19,645,139	20,368,844
Long-term debt	17,156,233	8,224,875	1,303,678
Deferred revenue	10	756,344
Other long-term liabilities	9,962,888	6,726,793	3,389,889
Net debt	(52,471,808)	(59,837,251)	(68,256,839)
Cash flow
Cash from operating activities	4,135,856	8,805,263	53,174,659
CAPEX	(5,491,491)	(18,523,655)	(43,285,807)
Cash from investing activities	(13,468,343)	(19,148,743)	(45,624,116)
Cash from financing activities	14,054,749	4,674,171	7,753,113
FCF	28,857,612	(8,529,407)	7,280,368
Balance
Cash	91,833,053	80,034,585	82,626,930
Long term investments	8,077,492	7,672,680	7,302,431
Excess cash	86,748,705	76,787,543	78,742,176
Stockholders' equity	26,156,006	34,818,809	(1,129,182)
Invested Capital	263,323,565	239,629,587	222,627,298
ROIC	11.79%	18.86%	26.93%
ROCE	12.50%	15.21%	31.15%
EV
Common stock shares outstanding	25,810	25,810	25,303
Price	33,300.00 13.27%	29,400.00 -39.51%	48,600.00 173.80%
Market cap	859,482,690 13.27%	758,822,555 -38.29%	1,229,719,968 181.99%
EV	818,011,713	706,522,644	1,166,006,242
EBITDA	45,444,779	49,621,003	74,008,250
EV/EBITDA	18.00	14.24	15.76
Interest	1,407,616	647,917	641,363
Interest/NOPBT	3.86%	1.53%	0.93%